Abstract Library

#4601 Pembrolizumab combined with cisplatin or carboplatin and etoposide in treatment naïve advanced Merkel cell carcinoma (MCC): The phase II PANDORA Trial

Introduction: MCC is a rare and aggressive skin neuroendocrine tumour with high metastatic potential and mortality. Therapeutic options in metastatic/unresectable MCC are based on immunotherapy or platinum-based chemotherapy. However, a subgroup of patients (pts) has primary immunoresistance disease, so it would be important discover active upfront combinations. PANDORA trial [NCT 06086288] is an open-label, multicentre, single-arm phase II trial evaluating the activity and safety of pembrolizumab (PEM) combined with platinum-based chemotherapy as 1st line treatment in pts with metastatic, unresectable or recurrence MCC. Supported in part by a research grant from Investigator-Initiated Studies Program of MSD.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Cingarlini S, Di Giacomo A, Borghesani M,

Keywords: Pembrolizumab, clinical trial, Merkel cell carcinoma, chemio-immunotherapy,

#4459 Sequential alkylating therapy and pembrolizumab induce near-complete response in high tumour mutational burden pancreatic neuroendocrine tumour: A case report

Introduction: Traditional treatment for neuroendocrine tumours (NETs), including surgery, somatostatin therapy, and targeted therapy, often fails in advanced disease. Alkylating therapy can increase tumour mutational burden (TMB), and the recent KEYNOTE-158 study approved pembrolizumab for advanced solid tumours with a high TMB.

Conference:

Presenting Author:

Authors: Paranjpe I, Hornbacker K, Vadde S, Fisher G, Shaheen S,

Keywords: pancreatic neuroendocrine tumour, immunotherapy, pembrolizumab, tumour mutational burden, TMB,

#3729 Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors

Introduction: Immune checkpoint inhibitors have not been shown to be active in well-differentiated NETs, with response rates

Conference:

Presenting Author: Strosberg J

Authors: Strosberg J, Al-Toubah T, Morse B, Haider M, Valone T,

Keywords: pembrolizumab, lenvatinib, neuroendocrine tumor, immunotherapy,

#3304 Ga-68/Lu-177 octreotate theranostic paradigm in metastatic Merkel cell carcinoma

Introduction: Merkel cell carcinoma (MCC) is a rare, aggressive, cutaneous neuroendocrine tumor with poor survival and significant propensity for metastasising. MCC is normally characterised by an up-regulation of somatostatin receptors (SSTR) which introduces the possibility for a targeted treatment approach using peptide receptor radionuclide therapy (PRRT).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lenzo N

Authors: Falzone N, Meyrick D, Lee B, Lenzo N,

Keywords: peptide receptor radionuclide therapy, Merkel cell carcinoma, Lu-177 octreotate, Ac-225 octreotate,

#3289 Short-interval, low-dose (SILD) Lu-177 DOTAiTATE therapy to overcome resistance to immunotherapy with PD-1 checkpoint inhibitors: Proof of concept to induce remission in patients with metastatic Merkel cell carcinoma and melanoma

Introduction: Immunotherapy with PD-1 immune checkpoint inhibitors (ICI) in Merkel cell carcinoma (MCC) or melanoma have proven efficacy.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Prasad V

Authors: Aicher A, Sindrilaru A, Beer A, Prasad V,

Keywords: PRRT, SILD, ICI, Merkel cell carcinoma, melanoma, tumor microenvironment remodelling,